OncoMatch/Clinical Trials/NCT06758375

Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients

Is NCT06758375 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Low-dose teclistamab for multiple myeloma, newly diagnosed.

Phase 2RecruitingHospital Universitario Dr. Jose E. GonzalezNCT06758375Data as of May 2026

Treatment: Low-dose teclistamab — This single-arm, open-label study aims to determine the efficacy and safety of low-dose, limited-duration teclistamab as a consolidation scheme in newly diagnosed multiple myeloma (NDMM) patients.

Check if I qualify

Extracted eligibility criteria

Cancer type

Multiple Myeloma

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: any treatment for multiple myeloma

History of previous treatment for MM

Cannot have received: allogeneic or autologous hematopoietic cell transplantation

History of allogeneic or autologous hematopoietic cell transplantation

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify